Time-Kill Assay Services for Antimicrobial Development
Antiinfectives Intelligence (Aii) offers state-of-the-art Time-Kill Assay services to evaluate the dynamic killing effects of antimicrobial agents. This advanced method
Read more
DISEASES
Irish Biotech Startup Aerska Secures $21M to Push Boundaries of Brain RNAi Therapies
Aerska, a newly formed biotechnology company focused on transforming the treatment of neurological diseases, has officially launched with $21 million
Read more
The Role of Microglia and T Cells in Age-Associated Decline
A recent study by Janos Groh and colleagues in Mikael Simons’ group at the Institute of Neuronal Cell Biology, Technical
Read more
Roche to Acquire 89bio in $3.5 Billion Deal Bolstering its MASH Pipeline
The definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read more
Merck’s KEYTRUDA QLEX™ Secures FDA Approval as First Subcutaneous Pembrolizumab Injection
Merck & Co., known as MSD outside of the United States and Canada, announced on Saturday that the U.S. Food
Read more
FDA Approves J&J’s Inlexzo™ Breakthrough Bladder Cancer Therapy
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved INLEXZO™ (gemcitabine intravesical system), a
Read more
Boehringer’s HERNEXEOS® Wins Accelerated FDA Nod in Lung Cancer
In a landmark decision for HER2-mutant lung cancer, the US FDA has granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® (zongertinib),
Read more
StressMarq Unveils Cutting-Edge Tau-441 (2N4R) Wild-Type Pre-formed Fibrils and Monomers (Baculovirus/Sf9)
StressMarq Biosciences, a market leader and pioneer in the field of fibrilized and oligomeric protein preparations for neurodegenerative disease research,
Read more
Sanofi Secures China Rights to RNAi Candidate for Hypertriglyceridemia from Arrowhead
In a major regional licensing agreement, Sanofi has entered into an asset purchase deal with Visirna Therapeutics, a majority-owned subsidiary
Read more
Lilly’s Jaypirca Outperforms Imbruvica in CLL Head-to-Head Phase 3 Trial
Eli Lilly’s Jaypirca (pirtobrutinib), the first and only FDA-approved non-covalent (reversible) BTK inhibitor, has met its primary endpoint in the
Read more